3rd Circ. Wipes Out FTC's $448M AbbVie Win

By Matthew Perlman (September 30, 2020, 8:06 PM EDT) -- The Third Circuit on Wednesday reversed a court-ordered $448 million penalty against AbbVie and Besins for allegedly delaying generic forms of the testosterone treatment AndroGel through sham litigation, pointing to the U.S. Supreme Court's Liu decision while concluding the Federal Trade Commission lacked disgorgement authority....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!